IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4050
Positioning
Market Dominance
Manufacturing
Medical Equipment
$33M
David A. Rosa
NeuroOne Medical Technologies Corporation focuses on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) recording, spinal cord stimulation, brain stimulation, and ablation solutions. The company is based in Eden Prairie, Minnesota.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$NMTC NEUROONE MEDICAL TECHNOLOGIES Corp | 36 | 42 | 21 | 30 | - | - | -53.5% | -39.9% | 55.6% | -77.8% | -61.9% | 250.3% | 0.0% | 34.0x | $33M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) receives a "Avoid" rating with a composite score of 35.6/100. It ranks #4050 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Lagging peers — losers tend to keep underperforming
Expensive relative to fundamentals — limited margin of safety
Average quality profile
High volatility — wider range of outcomes increases timing risk
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for NMTC.
View All Ratings| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 42 | 30 | +12ALPHA |
| MOMENTUM | 30 | 17 | +13ALPHA |
| VALUATION | 21 | 10 | +11ALPHA |
| INVESTMENT | 29 | 35 | -6DRAG |
| STABILITY | 32 | 19 | +13ALPHA |
| SHORT INT | 52 | 57 | -5NEUTRAL |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROE proxy -53.5% (sector -1.9%)
GM 56% vs sector 44%, OM -78% vs sector 3%
Capital turnover N/A, R&D intensity 48.0%
Rev growth 250%, 11yr history
Interest coverage -5.1x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) as Avoid with a composite score of 35.6/100 at a current price of $0.70. The stock falls in the bottom quintile, and the multi-factor weakness suggests a high probability of continued underperformance.
NEUROONE MEDICAL TECHNOLOGIES Corp holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 35.6/100 places it at rank #4050 in our full universe.
No Moat
High
Poor
Fair Value
Gross margins of 56% signal strong pricing power.
Stable competitive position in a defensive sector.
Weak momentum suggests persistent institutional selling pressure.
Vulnerability to macroeconomic shocks and interest rate volatility.
NEUROONE MEDICAL TECHNOLOGIES Corp represents a avoid based on multi-factor quantitative performance.
Our quantitative model flags NEUROONE MEDICAL TECHNOLOGIES Corp with an Avoid rating, assigning a composite score of 35.6/100 and 1 out of 5 stars. Ranked #4050 of 7,333 stocks, NMTC falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
NMTC's quality score of 42/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -53.5% (sector avg: -1.9%), gross margins of 55.6% (sector avg: 44.1%), net margins of -61.9% (sector avg: 1.0%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
NMTC registers a value score of just 21/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 5.36x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
NEUROONE MEDICAL TECHNOLOGIES Corp's investment score of 29/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 250.3% vs. a sector average of 6.7% and a return on assets of -39.9% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
NMTC is currently showing below-average momentum at 30/100, which may indicate weakening institutional interest or negative sentiment shifts. Revenue growth stands at 250.3% year-over-year, while a beta of 1.34 reflects its sensitivity to broader market moves. Investors should note that declining momentum can precede further price weakness, though contrarian opportunities sometimes emerge at these levels.
NMTC's stability score of 32/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 1.34 and a debt-to-equity ratio of 34.00x (sector avg: 0.2x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
The short interest score of 52/100 for NMTC suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include above-average market sensitivity (beta: 1.34), elevated leverage (D/E: 34.00x), micro-cap liquidity risk. With a $33M market cap (micro-cap), NEUROONE MEDICAL TECHNOLOGIES Corp may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
NEUROONE MEDICAL TECHNOLOGIES Corp is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4050 of 7,333 overall (45th percentile). Key comparisons include ROE of -53.5% trailing the -1.9% sector median and operating margins of -77.8% below the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While NMTC currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Value (21) would have the largest impact on the composite score.
ROE 2715% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 26% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 3200% BELOW SECTOR MEDIAN
Above 50MA
37.18%
Net New Highs
+51081
NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Q1 2026 Earnings Call Transcript February 17, 2026NeuroOne Medical Technologies Corporation beats earnings expectations.
NeuroOne (NMTC) Q1 2026 earnings call: $10.5M+ revenue guide, OneRF adoption, FDA clearance, drug-delivery acceleration & cash outlook—read now.
This article first appeared on GuruFocus. NeuroOne Medical Technologies Corp (NASDAQ:NMTC) is set to release its Q1 2026 earnings on Feb 17, 2026. The consensus estimate for Q1 2026 revenue is $2.68 million, and the earnings are expected to come in at -$0.04 per share.
NeuroOne Medical Technologies Corporation has been notified by Nasdaq that it is not in compliance with the minimum bid price requirement, and faces delisting if it fails to regain compliance within the grace period.
NeuroOne Medical Technologies reported strong Q3 2025 performance with 105% product revenue growth, improved gross margins, and promising clinical milestones for its OneRF ablation system, including the first patient achieving 12-month seizure freedom.